Moderna to Present at Upcoming Investor Conferences in November 2021

Rhea-AI Summary

Moderna (NASDAQ: MRNA) announces its participation in two upcoming virtual investor conferences:

• Bernstein Operational Decisions Conference on November 4, 2021 at 4:30 p.m. ET
• Credit Suisse 30th Annual Healthcare Conference on November 8, 2021 at 1:50 p.m. ET

Live webcasts will be available in the Investors section of Moderna's website and will be archived for at least 30 days post-event. Moderna, a leader in mRNA therapeutics, continues to innovate in vaccine development, notably against COVID-19.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences:

• Bernstein Operational Decisions Conference on Thursday, November 4, 2021 at 4:30 p.m. ET
• Credit Suisse 30^th Annual Healthcare Conference on Monday, November 8, 2021 at 1:50 p.m. ET

A live webcast of each presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at https://investors.modernatx.com/. A replay of each webcast will be archived on Moderna’s website for at least 30 days following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211028006164/en/

Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834

Lavina.Talukdar@modernatx.com

Source: Moderna, Inc.

FAQ

What conferences will Moderna (MRNA) participate in November 2021?

Moderna will participate in the Bernstein Operational Decisions Conference on November 4, 2021, and the Credit Suisse 30th Annual Healthcare Conference on November 8, 2021.

What time is the Bernstein Operational Decisions Conference for Moderna (MRNA)?

The Bernstein Operational Decisions Conference will take place on November 4, 2021, at 4:30 p.m. ET.

How can I watch Moderna's (MRNA) investor conference webcasts?

Live webcasts of Moderna's investor conference presentations will be available in the Investors section of their website.

Until when will the conference webcasts for Moderna (MRNA) be available?

The conference webcasts will be archived on Moderna's website for at least 30 days after the presentations.

What is the main focus of Moderna's (MRNA) business?

Moderna focuses on pioneering messenger RNA (mRNA) therapeutics and vaccines, including developments for COVID-19.